Released Aug 2, 2018, after the close
10-Q filed Aug 6, 2018, 37 days after period end · 0001493152-18-011019
Q2 2018 · 10-Q
Revenue$5.65M$5.65M +1.8% vs Q2 2017−1.9% vs Q1 2018
Net Income-$124.00K-$124.00K N/M vs Q2 2017N/M vs Q1 2018
EPS Diluted-$0.05-$0.05 N/M vs Q2 2017N/M vs Q1 2018
Operating Income-$27,000N/M
Operating Cash Flowderived$359,000−89.0%
Free Cash Flowderived$248,000−91.8%
Margins · derived
Operating margin-0.5%−0.0 pt vs Q2 2017
Net margin-2.2%+0.8 pt vs Q2 2017
What the release said
The release
Same quarter
| Metric | Q2 2018 | Q2 2017 | Q2 2016 | Q2 2015 |
|---|---|---|---|---|
| Revenue | $5.65M | $5.55M | $5.41M | $6.19M |
| Net Income | -$124.00K | -$164.00K | -$850.00K | -$2.63M |
| EPS Diluted | -$0.05 | -$0.07 | -$0.46 | -$1.43 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR